Tango Therapeutics, Inc.

NasdaqGM:TNGX 주식 보고서

시가총액: US$916.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tango Therapeutics 관리

관리 기준 확인 3/4

Tango Therapeutics' CEO는 Barbara Weber, Mar2017 에 임명되었습니다 의 임기는 7.25 년입니다. 총 연간 보상은 $ 3.39M, 18.5% 로 구성됩니다. 18.5% 급여 및 81.5% 보너스(회사 주식 및 옵션 포함). 는 $ 13.33M 가치에 해당하는 회사 주식의 1.31% 직접 소유합니다. 13.33M. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 3.4 년입니다.

주요 정보

Barbara Weber

최고 경영자

US$3.4m

총 보상

CEO 급여 비율18.5%
CEO 임기7.3yrs
CEO 소유권1.3%
경영진 평균 재임 기간1.4yrs
이사회 평균 재임 기간3.5yrs

최근 관리 업데이트

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Recent updates

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

CEO 보상 분석

Barbara Weber 의 보수는 Tango Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$112m

Dec 31 2023US$3mUS$626k

-US$102m

Sep 30 2023n/an/a

-US$100m

Jun 30 2023n/an/a

-US$107m

Mar 31 2023n/an/a

-US$111m

Dec 31 2022US$5mUS$575k

-US$108m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$92m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$12mUS$514k

-US$58m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$958kUS$492k

-US$52m

보상 대 시장: Barbara 의 총 보상 ($USD 3.39M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: Barbara 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Barbara Weber (67 yo)

7.3yrs

테뉴어

US$3,391,058

보상

Dr. Barbara L. Weber, M.D., has been the President, Director and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and also served as Chairperson. Dr. Weber serves as a Director of OPY A...


리더십 팀

이름위치테뉴어보상소유권
Barbara Weber
President7.3yrsUS$3.39m1.31%
$ 12.0m
Adam Crystal
President of Research & Development1.4yrsUS$3.11m0.025%
$ 232.4k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Levi Garraway
Founderno data데이터 없음데이터 없음
William Kaelin
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Timothy Lu
Founderno data데이터 없음데이터 없음
Antoni Ribas
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Timothy Redfern
Chief Financial Officerless than a year데이터 없음데이터 없음
Jannik Andersen
Chief Scientific Officerless than a year데이터 없음데이터 없음
Douglas Barry
Chief Legal Officer2.9yrs데이터 없음0.041%
$ 377.3k
Julie Carretero
Chief Human Resources Officerless than a year데이터 없음데이터 없음
Michael Palmieri
Head of Chemistry2.5yrs데이터 없음데이터 없음

1.4yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: TNGX 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Barbara Weber
President7.3yrsUS$3.39m1.31%
$ 12.0m
Alan Ashworth
Founder & Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
William Kaelin
Founder & Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Antoni Ribas
Founder & Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Alexis Borisy
Independent Chairman7.5yrsUS$171.53k0.0047%
$ 42.9k
Mace Rothenberg
Independent Director3.3yrsUS$141.53k0.0047%
$ 42.9k
Kanishka Pothula
Independent Directorless than a year데이터 없음데이터 없음
Lesley Calhoun
Independent Director3.3yrsUS$148.03k0%
$ 0
Malte Peters
Independent Director5.8yrsUS$139.03k0.0047%
$ 42.9k
John Ketchum
Independent Directorless than a yearUS$375.87k0%
$ 0
Ulrich Elling
Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
John Doench
Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음

3.5yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: TNGX 의 이사회경험(평균 재직 기간 3.4 년)으로 간주됩니다.